[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Brawijaya\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232",false,"NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.","ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[27,28,29],"Acute Coronary Syndromes (ACS)","Pneumonia","COPD (Chronic Obstructive Pulmonary Disease)",[31,32,33,34,28,35],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","RECRUITING","2026-05-16",{"date":39,"type":40},"2026-05-22","ACTUAL",{"date":42,"type":40},"2026-01-01",{"date":44,"type":21},"2026-10-10",{"name":46,"class":47},"University of Brawijaya","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100472067","hypogastric-plexus-block-and-ganglion-impar-block-for-cervical-and-endometrial-cancer-pain-management-100472067","NCT05427058","Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management","Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety","Inclusion Criteria:\n\n* Unbearable cancer pain that is resistant to WHO (World Health Organization) pain ladder at least 2 weeks medication\n* The patient is tired of taking medication orally or complications of current medication (respiratory depression, nausea, vomiting, opioid-induced constipation, gastrointestinal disturbances)\n* Patients with pelvic floor pain diagnosed by a (Fellow of Interventional Pain Practice) FIPP-certified pain specialist\n* Patients with pain in the perineum diagnosed by a FIPP-certified pain specialist\n* Numerical Rating Scale \\>4\n* \\>18 years old\n* Able and willing to sign an informed consent\n\nExclusion Criteria:\n\n* Refuse to be included in the research\n* Blood clotting disorders (including taking anticoagulant drugs)\n* Local infection in the area of action\n* Loss to follow up\n\nDrop-out Criteria:\n\n* Loss to follow up\n* Intervention complications occur\n* Failed intervention","FEMALE",{"count":58,"type":21},36,[60],"NA","This study compared the efficacy and safety of superior hypogastric plexus block and ganglion impar block procedures on the management of pelvic and perineal cancer pain in patients with cervical and endometrial cancer",[63,64],"Cervical Cancer","Endometrial Cancer",[66,63,64,67,68,69],"Perineal Pain","Superior Hypogastric Plexus Block","Ganglion Impar Block","pelvic pain","2025-07-07",{"date":72,"type":40},"2025-07-10",{"date":74,"type":40},"2024-07-23",{"date":76,"type":21},"2026-01-30",{"name":46,"class":47},""]